

PTO/SB/08A (10-01)

Approved for use through 10/31/2002.OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/816,698	
			Filing Date	April 2, 2004	
			First Named Inventor	Mien-Chie Hung	
			Art Unit	1645	
Examiner Name	Not Yet Assigned				
Sheet	1	of	3	Attorney Docket Number	AH-UTSC:791US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
	AA*	US-6,638,762	10-28-2003	Chang et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	BA	WO-98/33903	08-06-1998	Molloy		
	BB	AU-5742198	08-25-1998	Molloy		
	BC	WO-00/26343	05-11-2000	Eckert et al.		
	BD	EP-1009820	06-21-2000	Molloy		
	BE	JP-2001218587	08-14-2001	Chao		

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant

¹ Applicant's unique citation designation number (optional). ² See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	Anderson et al., "Breast cancer-specific expression of the <i>Candida albicans</i> cytosine deaminase gene using a transcriptional targeting approach," <i>Cancer Gene Therapy</i> , 7(6): 845-852, 2000.	
	CB	Bauman et al., "Differential Immunohistochemical Staining for DNA Topoisomerase II α and β in Human Tissues and for DNA Topoisomerase II β in Non-Hodgkin's Lymphomas," <i>Mod. Pathol.</i> , 10(3): 168-175, 1997.	
	CC	Casey et al., "Deletional analysis of the promoter region of the human transferrin receptor gene," <i>Nucleic Acids Research</i> , 16(2): 629-646, 1988.	
	CD	Donello et al., "Woodchuck Hepatitis Virus Contains a Tripartite Posttranscriptional Regulatory Element," <i>J. Virology</i> , 72(6): 5085-5092, 1998.	
	CE	Fuernkranz et al., "Differential tissue localization of oviduct and erythroid transferrin receptors," <i>Proc. Natl. Acad. Sci. USA</i> , 88: 7505-7508, 1991.	
	CF	Guillou et al., "Sertoli Cell-specific Expression of the Human Transferrin Gene: Comparison with the Liver-specific Expression," <i>J. Biol. Chem.</i> , 266(15): 9876-9884, 1991.	
	CG	Hirsch et al., "Mitogenic activation of the transferrin receptor gene promoter is modulated by inhibitors of tyrosine kinases and tyrosine phosphatases," <i>Recept Signal Transduct.</i> , 6(3-4): 121-9, 1996.	
	CH	Hochhauser et al., "Cloning and characterization of the 5' flanking region of the human topoisomerase II alpha gene," <i>J. Biol. Chem.</i> , 267(26): 18961-5, 1992.	
	CI	Idzerda et al., "Expression from the Transferrin Gene Promoter in Transgenic Mice," <i>Mol. Cell. Biol.</i> , 9(11): 5154-5162, 1989.	
	CJ	Isomura et al., "The Human Cytomegalovirus Major Immediate-Early Enhancer Determines the Efficiency of Immediate-Early Gene Transcription and Viral Replication in Permissive Cells at Low Multiplicity of Infection," <i>Journal of Virology</i> , 77(6): 3602-3614, 2003.	
	CK	Iyer et al., "Two-step transcriptional amplification as a method for imaging reporter gene	
Examiner Signature			Date Considered
			3/17/06

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)			Complete if Known		
			Application Number	10/816,698	
			Filing Date	April 2, 2004	
			First Named Inventor	Mien-Chie Hung	
			Art Unit	1645	
			Examiner Name	Not Yet Assigned	
Sheet	2	of	3	Attorney Docket Number	AH-UTSC:791US

		expression using weak promoters," <i>PNAS</i> , 98(25): 14595-14600, 2001.	
CL		Katabi et al., "Hexokinase Type II: A Novel Tumor-Specific Promoter for Gene-Targeted Therapy Differentially Expressed and Regulated in Human Cancer Cells," <i>Human Gene Therapy</i> , 10: 155-164, 1999.	
CM		Kawabata, "Regulation of expression of murine transferrin receptor 2," <i>Blood</i> , 98(6): 1949-1954, 2001.	
CN		Kugler et al., "Tissue-specificity of liver gene expression: a common liver-specific promoter element," <i>Nucleic Acids Research</i> , 16(8): 3165-3174, 1988.	
CO		Lu et al., "Enhanced Gene Expression in Breast Cancer Cells <i>in Vitro</i> and Tumors <i>in Vivo</i> ," <i>Molecular Therapy</i> , 6(6): 783-792, 2002.	
CP		Maeda et al., "A minimum c-erbB-2 promoter-mediated expression of herpes simplex virus thymidine kinase gene confers selective cytotoxicity of human breast cancer cells to ganciclovir," <i>Cancer Gene Therapy</i> , 8(11): 890-896, 2001.	
CQ		Mendelzon et al., "The binding site for the liver-specific transcription factor Tf-LF1 and the TATA box of the human transferrin gene promoter are the only elements necessary to direct liver-specific transcription <i>in vitro</i> ," <i>Nucleic Acids Research</i> , 18(19): 5717-5721, 1990.	
CR		Mo et al., "Overexpression of human DNA topoisomerase II alpha by fusion to enhanced green fluorescent protein," <i>Biotechnol.</i> , 25(6): 1052-7, 1998.	
CS		Qiao et al., "Tumor-specific transcriptional targeting of suicide gene therapy," <i>Gene Therapy</i> , 9: 168-175, 2002.	
CT		Radetzki et al., "The apoptosis promoting Bcl-2 homologues Bak and Nbk/Bik overcome drug resistance in Mdr-1-negative and Mdr-1-overexpressing breast cancer cell lines," <i>Oncogene</i> , 21(2): 227-38, 2002.	
CU		Sandford et al., "Rat Cytomegalovirus Major Immediate-Early Enhancer Switching Results in Altered Growth Characteristics," <i>Journal of Virology</i> , 75(11): 5076-5083, 2001.	
CV		Sato et al., "Optimization of adenoviral vectors to direct highly amplified prostate-specific expression for imaging and gene therapy," <i>Mol. Ther.</i> , 8(5): 726-37, 2003.	
CW		Shindelman et al., "Demonstration of the Transferrin Receptor in human breast cancer tissue. Potential marker for identifying dividing cells," <i>Int. J. Cancer</i> , 27:329-334, 1981.	
CX		Shterman et al., "Comparison of Transferrin Receptors, Iron Content and Isoferritin profile in normal and malignant human breast cell lines," <i>Pathobiol.</i> , 59: 19-25, 1991.	
CY		Theisen et al., "A C/EBP-Binding Site in the Transferring Promoter Is Essential for Expression in the Liver but Not the Brain of Transgenic Mice," <i>Mol. Cell. Biol.</i> , 13(12): 7666-7676, 1993.	
CZ		Tong et al., "The Pro-apoptotic Protein, Bik, Exhibits Potent Antitumor Activity That Is Dependent on Its BH3 Domain," <i>Molecular Cancer Therapeutics</i> , 1: 95-102, 2001.	
CA1		Verma et al., "Structural analysis of the human pro-apoptotic gene <i>Bik</i> : Chromosomal localization, genomic organization and localization of promoter sequences," <i>Gene</i> , 254(1-2): 157-162, 2000.	
CB1		Xie et al., "Adenovirus-mediated tissue-targeted expression of a caspase-9-based artificial death switch for the treatment of prostate cancer," <i>Cancer Res.</i> , 61(18): 6795-804, 2001.	
CC1		Zakin, "Regulation of transferrin gene expression," <i>The FASEB Journal</i> , 6: 3253-3258, 1992.	
CD1		Zhang et al., "A Gene-Specific Promoter in Transgenic Mice Directs Testis-Specific Demethylation Prior to Transcriptional Activation <i>In Vivo</i> ," <i>Biology of Reproduction</i> , 59: 284-292, 1998.	
CE1		Zhang et al., "A small composite probasin promoter confers high levels of prostate-specific gene expression through regulation by androgens and glucocorticoids <i>in vitro</i> and <i>in vivo</i> ," <i>Endocrinology</i> , 141(12): 4698-710, 2000.	
CF1		Zhang et al., "Molecular engineering of a two-step transcription amplification (TSTA) system for transgene delivery in prostate cancer," <i>Mol. Ther.</i> , 5(3): 223-32, 2002.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not

Examiner Signature		Date Considered	3/17/06
--------------------	---	-----------------	---------

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/816,698
				Filing Date	April 2, 2004
				First Named Inventor	Mien-Chie Hung
				Art Unit	1645
				Examiner Name	Not Yet Assigned
Sheet	3	of	3	Attorney Docket Number	AH-UTSC:791US

considered. Include copy of this form with next communication to applicant.

¹Applicant's unique citation designation number (optional). ²Applicant is to place a check mark here if English language Translation is attached.

Examiner Signature		Date Considered	3/17/06
-----------------------	---	--------------------	---------



PTO 85/03A (10-01)
Approved for use through 10/31/2002 OMB C651-0051
U. S. Patent and Trademark Office: U. S. DEPARTMENT OF COMMERCE
Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/816,698
				Filing Date	April 2, 2004
				First Named Inventor	Mien-Chie Hung
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	AH-UTSC:791US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			

FOREIGN PATENT DOCUMENTS							
Examiner Initials*	Cite No. ¹	Foreign Patent Document		Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ⁴	Number-Kind Code ² (if known)				
	BA		WO-99/16787	04-08-1999			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.


¹ Applicant's unique citation designation number (optional). ² See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 18 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS					
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.			T ²
	CA	Elangovan, B. et al.; "Functional dissection of the pro-apoptotic protein bik: Heterodimerization with anti-apoptosis proteins is insufficient for induction of cell death". J. Biol. Chem., (1997) Vol. 272, No. 39, pp. 24494-24498.			
	CB	Boyd, J., et al., "Bik, a Novel Death-Inducing Protein Shares a Distinct Sequence Motif with Bel-2 Family Proteins and Interacts with Viral and Cellular Survival-Promoting Proteins", Oncogene (1995) Vol. 11, No. 9, pp. 1921-1928.			
	CC	Li, Y. et al.; "Enhancement of Bik antitumor effect by Bik Mutants." Cancer Research, (2003), Vol. 63, No. 22, pp. 7630-7633.			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 809. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

25503299.1 Examiner Signature		Date Considered	3/17/06
-------------------------------------	--	--------------------	---------



10 816 698

PTO/SB/08A (10-01)

Approved for use through 10/31/2002.OMB 0851-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	Not Yet Assigned
				Filing Date	Concurrently Herewith
				First Named Inventor	Mien-Chie Hung
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	AH-UTFC:791W00

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number Number-Kind Code ² (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ⁶
	BA	WO-99/16787	04-08-1999			

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	Elangovan, B. et al.; "Functional dissection of the pro-apoptotic protein bik: Heterodimerization with anti-apoptosis proteins is insufficient for induction of cell death". J. Biol. Chem., (1997) Vol. 272, No. 39, pp. 24494-24498.	
	CB	Boyd, J., et al., "Bik, a Novel Death-Inducing Protein Shares a Distinct Sequence Motif with Bel-2 Family Proteins and Interacts with Viral and Cellular Survival-Promoting Proteins", Oncogene (1995) Vol. 11, No. 9, pp. 1921-1928.	
	CC	Li, Y. et al.; "Enhancement of Bik antitumor effect by Bik Mutants." Cancer Research, (2003), Vol. 63, No. 22, pp. 7630-7633.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

25488303.1 Examiner Signature		Date Considered	3/17/06
-------------------------------------	--	--------------------	---------



PTO/SB/08A (10-01)

Approved for use through 10/31/2002.OMB 0651-0031

U. S. Patent and Trademark Office: U.S. DEPARTMENT OF COMMERCE

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control number.

Substitute for form 1449A/PTO INFORMATION DISCLOSURE STATEMENT BY APPLICANT (use as many sheets as necessary)				Complete if Known	
				Application Number	10/816,698
				Filing Date	April 2, 2004
				First Named Inventor	Mien-Chie Hung
				Art Unit	N/A
				Examiner Name	Not Yet Assigned
Sheet	1	of	1	Attorney Docket Number	AH-UTSC:791US

U.S. PATENT DOCUMENTS					
Examiner Initials*	Cite No. ¹	Document Number	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code ² (if known)			
		60/559,111	04-02-2004	Hung, Mien-Chie, et al.	

FOREIGN PATENT DOCUMENTS						
Examiner Initials*	Cite No. ¹	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T ³
		Country Code ³ -Number ⁴ -Kind Code ⁵ (if known)				

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² See attached Kinds Codes of USPTO Patent Documents at www.uspto.gov or MPEP 901.04. ³ Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). ⁴ For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the application number of the patent document. ⁵ Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. ⁶ Applicant is to place a check mark here if English language Translation is attached.

NON PATENT LITERATURE DOCUMENTS			
Examiner Initials*	Cite No. ¹	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T ²
	CA	Bartke, T., et al.; p53 upregulates cFLIP, inhibits transcription of NF-kB-regulated genes and induces caspase-8-independent cell death in DLD-1 cells, Oncogene (2001) Vol. 20, pp. 571-580.	
	CB	Zou, Yiyu, et al.; Systemic tumor suppression by the proapoptotic gene bik1, Cancer Research (January 2002), Vol. 62, pp. 8-12.	
	CC	Daniel, Peter T. et al.; Expression of the death gene bik/Nbk promotes sensitivity to drug-induced apoptosis in corticosteroid-resistant t-cell lymphoma and prevents tumor growth in severe combined immunodeficient mice, Neoplasia (August 1999) Vol. 94, No. 3, pp. 1100-1107.	
	CD	Han, Jeonghoon, et al.; induction of apoptosis by human Nbk/Bik, a BH3-containing protein that interacts with E1B 19K, Molecular and Cellular Biology (October 1996), pp. 5857-5864.	
	CE	Panaretakis, Theocharis, et al.; Activation of bak, bax, and BH3-only proteins in the apoptotic response to doxorubicin, Journal of Bio. Chem. (November 2002), Vol. 277, No. 46, pp. 44317-44326.	
	CF	Friedman, Debbie, et al.; Ecteinascidin-743 inhibits activated but not constitutive transcription, Cancer Research, (June 2002) Vol. 62, pp. 3377-3381.	
	CG	Verma, Sulekha, et al.; Phosphorylation of the pro-apoptotic protein BIK, Journal of Bio. Chem., (February 2001) Vol. 276, No.7, pp. 4671-4676.	

*EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant.

¹ Applicant's unique citation designation number (optional). ² Applicant is to place a check mark here if English language Translation is attached.

25433831.1 Examiner Signature		Date Considered	3/17/06
-------------------------------------	--	--------------------	---------